Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix

Cancer Epidemiology Biomarkers and Prevention

Volumn 6, Issue 4, 1997, Pages 233-237

  Shah, Keerti V ^a,c   Viscidi, Raphael P ^b   Alberg, Anthony J ^a   Helzlsouer, Kathy J ^a   Comstock, George W ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBODY TITER; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; RISK FACTOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

EID: 0030978269     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. IARC. Monograph on the Evaluation of Carcinogenic Risks to Humans. Vol. 64: Human Papillomaviruses. Lyon, France: IARC, 1995.
2. Muñoz, N., Bosch, F. X., deSanjosé, S., Tafur, L., Izarzugaza, I., Gili, M., Viladiu, P., Navarro, C., Martos, C., Ascunce, N., Gonzalez, L. C., Kaldor, J. M., Guerrero, E., Lörincz, A., Santamaria, M., Alonso de Ruiz, P., Aristizabal, N., and Shah, K. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int. J. Cancer, 52: 743-749, 1992.
3. Bosch, F. X., Manos, M. M, Muñoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., Shah, K. V., and the International Biological Study on Cervical Cancer Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst., 87: 796-802, 1995.
4. Schiffman, M. H., Bauer, H. M., Hoover, R. N., Glass, A. G., Cadell, D. M., Rush, B. B., Scott, D. R., Sherman, M. E., Kurman, R. J., Wacholder, S., Stanton, C. K., and Manos, M. M. Epidemiologic evidence showing that HPV infection causes most cervical intraepithelial neoplasia. J. Natl. Cancer Inst., 85: 958-964, 1993.
5. zur Hausen, H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. In: H. zur Hausen (ed.), Human Pathogenic Papillomaviruses, pp. 131-156. Heidelberg: Springer-Verlag, 1994.
6. Shah, K. V., and Howley, P. M. Papillomaviruses. In: B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (eds.), Virology, Ed. 3, pp. 2077-2109. Philadelphia, PA: Lippincott-Raven Publ., 1996.
7. Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Bechmann, A. M., DeRouen, T. A., Galloway, D. A., Vernon, D., and Kiviat, N. B. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med., 327: 1272-1278, 1992.
8. Kirnbauer, R., Hubbert, N. L., Wheeler, C. M., Becker, T. M., Lowy, D. R., and Schiller, J. T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. Natl. Cancer Inst., 86: 494-499, 1994.
9. Schiller, J. T., and Roden, R. B. S. Papillomavirus-like particles. Papillomavirus Rep., 6: 121-128, 1995.
10. Lehtinen, M., Dillner, J., Knekt, P., Luostarinen, T., Aromaa, A., Kirnbauer, R., Koskela, P., Paavonen, J., Peto, R., Schiller, J. T., and Hakama, M. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. Br. Med. J., 312: 537-539, 1996.
11. Batieha, A. M., Armenian, H. K., Norkus, E. P., Morris, J. S., Spate, V. E., and Comstock, G. W. Serum micronutrients and the subsequent risk of cervical cancer in a population-based nested case-control study. Cancer Epidemiol., Biomarkers & Prev., 2: 335-339, 1993.
12. Ries, L. A., Hankey, B. F., Miller, B. A., Hartman, A. M., and Edwards, B. K. Cancer Statistics Review 1973-88. NIH Publication No. 91-2789. Bethesda, MD: National Cancer Institute, 1991.
13. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R., and Schiller, J. T. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol., 67: 6929-6936, 1993.
14. Viscidi, R. P., Kotloff, K. L., Clayman, B., Russ, K., Shapiro, S., and Shah, K. V. Prevalence of antibodies to HPV type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol., 4: 122-126, 1997.
15. Kwa, H. G., Cleton, F., Wang, D. Y., Bulbrook, R. D., Bulstrode, J. C., Hayward, J. L., Millis, R. R., and Cuzick, J. A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int. J. Cancer., 28: 673-676, 1981.
16. Schlesselman, J. J. Case-Control Studies. Design, Conduct, Analysis, pp. 213-216. New York: Oxford University Press, 1982.
17. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research, Vol. 1. The Analysis of Case-Control Studies, pp. 248-278. Lyon, France: IARC, 1980.
18. Winkelstein, W. Smoking and cervical cancer-current status: a review. Am. J. Epidemiol., 131: 945-957, 1990.
19. Daly, M. B., Bookman, M. A., and Lerman, C. E. Female reproductive tract: cervix, endometrium, and ovary. In: P. Greenwald, B. S. Kramer, and D. L. Weed (eds.), Cancer Prevention and Control, pp 585-610. New York: Marcel Dekker, 1995.